Fludarabine
Microsatellite Instability
Udai KammulaSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Microsatellite Instability cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Fate Therapeutics | Phase 2 | B |
Nivolumab Fate Therapeutics | Phase 2 | B |
Atezolizumab Fate Therapeutics | Phase 2 | B |
Cyclophosphamide Udai Kammula | Phase 2 | B |
Avelumab ImmunityBio, Inc. | Phase 3 | B |
View all 14 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →